Jeffrey Yachnin

2.9k total citations
53 papers, 1.4k citations indexed

About

Jeffrey Yachnin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Jeffrey Yachnin has authored 53 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 12 papers in Immunology. Recurrent topics in Jeffrey Yachnin's work include Cancer Immunotherapy and Biomarkers (16 papers), Cancer Treatment and Pharmacology (9 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Jeffrey Yachnin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Cancer Treatment and Pharmacology (9 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Jeffrey Yachnin collaborates with scholars based in Sweden, United States and Denmark. Jeffrey Yachnin's co-authors include Hans Ehrsson, Inger Wallin, Sten Nilsson, Sören Lehmann, Ove Andrén, Ali Moshfegh, Ulf Tidefelt, Bertil Uggla, Honar Cherif and Vladimir J.N. Bykov and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Jeffrey Yachnin

44 papers receiving 1.3k citations

Peers

Countries citing papers authored by Jeffrey Yachnin

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Yachnin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Yachnin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Yachnin more than expected).

Fields of papers citing papers by Jeffrey Yachnin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Yachnin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Yachnin. The network helps show where Jeffrey Yachnin may publish in the future.

Co-authorship network of co-authors of Jeffrey Yachnin

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Yachnin. A scholar is included among the top collaborators of Jeffrey Yachnin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Yachnin. Jeffrey Yachnin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	581 Preliminary phase 1 results of clinical trial investigating BI-1910, a tumor necrosis factor receptor 2 (TNFR2) agonist, in solid tumor cancer patients 2025 ·Regular and Young Investigator Award Abstracts ·(unknown), Bernard Doger, Jeffrey Yachnin, (unknown), Irene Moreno, Ana Carneiro, Alejandro Falcón, (unknown), Ingrid Karlsson, (unknown), (unknown), Linda Mårtensson, Oliver Schönborn‐Kellenberger, Anette Sundstedt, Ingrid Teige, (unknown), (unknown), Johan Wallin, Björn Frendéus, Andrés McAllister	0
2	925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors: Interim safety and efficacy analysis from HRO761 single agent dose escalation 2025 ·Annals of Oncology ·Michael B. Foote, Jingjing Li, Daniel Shao-Weng Tan, Aitana Calvo, Rachel Galot, Elena Garralda, Tormod Kyrre Guren, Antoine Italiano, (unknown), Zev A. Wainberg, Jeffrey Yachnin, Timothy A. Yap, Ruben de Kanter, Nuno Grande, (unknown), Dragana Janković, Laurent Sansregret, Chao Zhang, Ankur K. Nagaraja, Yasutoshi Kuboki	0
3	First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), Peter Ellmark, (unknown), Lena Schultz, Sumeet Ambarkhane, Jeffrey Yachnin, Gustav Ullenhag	1
4	Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer 2024 ·Clinical Cancer Research ·Eric Van Cutsem, Joëlle Collignon, Rikke Løvendahl Eefsen, Sebastian Ochsenreither, Zanete Zvirbule, (unknown), Dirk Arnold, (unknown), Per Pfeiffer, Jeffrey Yachnin, (unknown), (unknown), Annika Sanfridson, Nedjad Losic, Ignacio Garcia‐Ribas, Dominique Tersago, Ahmad Awada	2
5	19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab. 2024 ·Journal of Clinical Oncology ·Kristoffer Staal Rohrberg, Zsuzsanna Pápai, Rikke Løvendahl Eefsen, Jeffrey Yachnin, Ana Carneiro, Sean H. Lim, Harriet S. Walter, István Láng, Edvard Abel, Kirstie L.S. Cleary, Mark S. Cragg, Robert Oldham, (unknown), (unknown), Ingrid Karlsson, Johan Wallin, Michael Chisamore, Ingrid Teige, Björn Frendéus, Andrés McAllister	1
6	Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer 2024 ·JAMA Network Open ·Heikki Joensuu, Judith Fraser, Hans Wildiers, Riikka Huovinen, Päivi Auvinen, Meri Utriainen, Kenneth Villman, Päivi Halonen, (unknown), Minna Tanner, Liisa Sailas, Taina Turpeenniemi‐Hujanen, Jeffrey Yachnin, Teppo Huttunen, Patrick Neven, Peter Canney, Vernon Harvey, Pirkko‐Liisa Kellokumpu‐Lehtinen, Henrik Lindman	0
7	1073TiP A phase I/IIa first in-human phase I study of BI 1910, a monoclonal antibody agonistic to TNFR2, as a single agent and in combination with pembrolizumab in subjects with advanced solid tumors 2024 ·Annals of Oncology ·(unknown), (unknown), Jeffrey Yachnin, Kristoffer Staal Rohrberg, (unknown), (unknown), Ingrid Karlsson, (unknown), L. Mårtensson, (unknown), (unknown), Michael Chisamore, Johan Wallin, Ingrid Teige, Björn Frendéus, Andrés McAllister	0
8	Abstract OT3-24-01: ReFocus: A Phase 1/2 Study of the Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Advanced Solid Tumors Including Breast Cancer 2023 ·Cancer Research ·Suneel D. Kamath, David Tai, Irene Moreno, Hani M. Babiker, Zhaohui Jin, Changhoon Yoo, Fabien Ricard, (unknown), Jermaine Coward, Jia Liu, Frans L. Opdam, (unknown), Mariano Ponz‐Sarvisé, Jeffrey Yachnin, Richard D. Kim, Joon Oh Park, Vivek Subbiah, Alison M. Schram	0
9	Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration‐resistant prostate cancer 2023 ·The Prostate ·(unknown), (unknown), Pedro Fonseca, Sue‐Hwa Lin, Christopher J. Logothetis, Jeffrey Yachnin, Anders Ullén, Theocharis Panaretakis	4
10	A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors 2023 ·International Journal of Radiation OncologyBiologyPhysics ·Michael A. Samuels, (unknown), Voichita Bar‐Ad, Juergen Dunst, Baukelien van Triest, Jeffrey Yachnin, (unknown), Mirjam Kuipers, (unknown), (unknown), Giuseppe Locatelli, (unknown), Esther G.C. Troost	36
11	622 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·David J. Pinato, Ruth Plummer, Martin Gutierrez, Jeffrey Yachnin, (unknown), Martin Højgaard, Knut B. Smeland, William J. Edenfield, Hans Prenen, Lars Ny, Alan Anthoney, Nuria Kotecki, Stefan N. Symeonides, Louis Viviers, (unknown), (unknown), Udai Banerji	3
12	Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223 2021 ·European Journal of Nuclear Medicine and Molecular Imaging ·Maarten J. van der Doelen, (unknown), Yuanjun Ma, Niven Mehra, Jeffrey Yachnin, Winald R. Gerritsen, Sten Nilsson, Inge M. van Oort, Anders Ullén	17
13	611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study 2021 ·Annals of Oncology ·Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, Jeffrey C. Goh, Ulka N. Vaishampayan, Ronald de Wit, Tuomo Alanko, Satoshi Fukasawa, Ken‐ichi Tabata, (unknown), Raanan Berger, Kristiina Ojamaa, Christopher Hoimes, Ahmet Sezer, Aurelius Omlin, Jeffrey Yachnin, Chen Niu, Christian Poehlein, Charles Schloss, Johann S. de Bono	7
14	Safety and activity of sorafenib in addition to vinflunine in post-platinum metastatic urothelial carcinoma (Vinsor): Phase I trial 2018 ·European Urology Supplements ·(unknown), Helle Pappot, Mads Agerbæk, (unknown), Fredrik Jäderling, Jeffrey Yachnin, Per Grybäck, Hans von der Maase, (unknown)	2
15	The In Vitro Stability of Circulating Tumour DNA 2016 ·PLoS ONE ·(unknown), Jeffrey Yachnin, Henrik Grönberg, Johan Lindberg	17
16	An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors 2014 ·Cancer Chemotherapy and Pharmacology ·Pierre Maison‐Blanche, Shaker R. Dakhil, Ari David Baron, Sylvie Rottey, (unknown), Gedske Daugaard, Jean-Pascal Machiels, William R. Conkright, Sunil Sharma, Patricia M.M.B. Soetekouw, Jeffrey Yachnin, Lisa Sengeløv, Peter J. Van Veldhuizen, Sanjiv S. Agarwala, Dorothée Sémiond, Mustapha Chadjaa, Liji Shen, James L. Wade	1
17	Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study 2007 ·The Lancet Oncology ·Sten Nilsson, Lars Franzén, Christopher Parker, (unknown), René Blom, Jan Tennvall, Bo Lennernäs, Ulf Petersson, Dag Clement Johannessen, M. Sokal, K. Pigott, Jeffrey Yachnin, Michael Garkavij, Peter Strang, Johan Harmenberg, B. Bolstad, Øyvind S. Bruland	354
18	Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate 2006 ·European Journal of Pharmaceutical Sciences ·Elin Jerremalm, Inger Wallin, Jeffrey Yachnin, Hans Ehrsson	28
19	Pharmacokinetics of Oxaliplatin in Humans 2002 ·Medical Oncology ·Hans Ehrsson, Inger Wallin, Jeffrey Yachnin	86
20	Synthesis and cytotoxicity of the dihydrated complex of oxaliplatin 2002 ·Cancer Letters ·Pernilla Videhult Pierre, Jeffrey Yachnin, Elin Jerremalm, Rolf Lewensohn, Hans Ehrsson	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact